Home>>Signaling Pathways>> GPCR/G protein>> 5-HT Receptor>>SB269970 HCl

SB269970 HCl (Synonyms: SB-269970A)

Catalog No.GC10769

SB269970 HCl is a potent, selective and brain-penetrant 5-HT7 receptor antagonist with a pKi of 8.3.

Products are for research use only. Not for human use. We do not sell to patients.

SB269970 HCl Chemical Structure

Cas No.: 261901-57-9

Size Price Stock Qty
10mM (in 1mL DMSO)
$133.00
In stock
10mg
$121.00
In stock
50mg
$401.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SB269970 HCl is a potent and selective antagonist of 5-HT7 receptor with pKi value of 8.3 [1].

SB269970 is a selective antagonist of 5-HT7 receptor. It shows at least 100-fold selective against 5-HT7 over a variety of receptors and enzymes. SB269970 prevents 5-CT from binding to h5-HT7(a) in H293 cells and human cloned 5-HT7 receptor in guinea-pig cerebral cortex membranes with pKi values of 8.9 and 8.3, respectively. SB269970 also inhibits adenylyl cyclase activity stimulated by 5-CT both in 5-HT7(a)/ HEK293 (pA2 of 8.5) membranes and in guinea-pig hippocampus (pKB of 8.3). In vehicle-treated animals, SB269970 almost completely inhibits the 5-CT-induced hypothermia with ED50 value of 2.96mg/kg [1].

References:
[1] Hagan J J, Price G W, Jeffrey P, et al. Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist. British journal of pharmacology, 2000, 130(3): 539-548.

Reviews

Review for SB269970 HCl

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SB269970 HCl

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.